{"id":17218,"date":"2022-10-25T01:03:39","date_gmt":"2022-10-24T23:03:39","guid":{"rendered":"http:\/\/www.infokuryr.cz\/n\/?p=17218"},"modified":"2022-10-24T13:47:40","modified_gmt":"2022-10-24T11:47:40","slug":"bomba-z-japonska-vakciny-covid-se-4krat-vyssim-rizikem-myokarditidy","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2022\/10\/25\/bomba-z-japonska-vakciny-covid-se-4krat-vyssim-rizikem-myokarditidy\/","title":{"rendered":"Bomba z Japonska: Vakc\u00edny COVID se 4kr\u00e1t vy\u0161\u0161\u00edm rizikem myokarditidy"},"content":{"rendered":"
<\/div>\n

Extr\u00e9mn\u011b vysok\u00e1 pravd\u011bpodobnost \u00famrt\u00ed na myokarditidu<\/span><\/h2>\n
\n
\n

Dal\u0161\u00ed studie, tentokr\u00e1t z Japonska, vyvol\u00e1v\u00e1 obavy ohledn\u011b bezpe\u010dnostn\u00edch sign\u00e1l\u016f mRNA vakc\u00edny COVID-19.\u00a0Spoluautor Rokuro Hama, \u0159editel Japonsk\u00e9ho institutu farmakovigilance, japonsk\u00e9 agentury pro post-vakcina\u010dn\u00ed dohled, uv\u00e1d\u00ed ve sv\u00e9 zpr\u00e1v\u011b ned\u00e1vno zve\u0159ejn\u011bn\u00e9 na\u00a0<\/span>p\u0159edtiskov\u00e9m serveru medRxiv.<\/span><\/a>rostouc\u00edch obav.\u00a0Tato sofistikovan\u00e1 japonsk\u00e1 skupina dodr\u017eovala sv\u016fj \u00fakol s velkou pe\u010dlivost\u00ed.\u00a0Uv\u00e1d\u011bj\u00ed, \u017ee \u00famrtnost na myokarditidu (MMRR) a jejich intervaly spolehlivosti (95 %) po pod\u00e1n\u00ed vakc\u00edn COVID-19 ve srovn\u00e1n\u00ed s b\u011b\u017enou referen\u010dn\u00ed populac\u00ed za posledn\u00ed t\u0159i roky vzrostly nejen u mlad\u00e9 dosp\u011bl\u00e9 populace (nejvy\u0161\u0161\u00ed MMRR v 30 s 6,69), ale byly tak\u00e9 v\u00fdrazn\u011b vy\u0161\u0161\u00ed u star\u0161\u00edch lid\u00ed.\u00a0<\/span>P\u0159evratn\u00fd poznatek<\/span><\/strong>\u00a0:<\/span>Japon\u0161t\u00ed auto\u0159i uv\u00e1d\u011bj\u00ed, \u017ee riziko myokarditidy u o\u010dkovan\u00fdch COVID-19 m\u016f\u017ee b\u00fdt \u010dty\u0159ikr\u00e1t vy\u0161\u0161\u00ed ne\u017e zjevn\u00e9 MMRR, vezmeme-li v \u00favahu \u00fa\u010dinek u zdrav\u00fdch o\u010dkovan\u00fdch.\u00a0Uv\u00e1d\u011bj\u00ed: \u201eJe t\u0159eba vz\u00edt v \u00favahu i m\u00e9n\u011b hl\u00e1\u0161en\u00e1 \u00famrt\u00ed po o\u010dkov\u00e1n\u00ed, jak nazna\u010duje extr\u00e9mn\u011b vysok\u00fd pom\u011br \u00famrtnosti na myokarditidu (205,60; 133,52 a\u017e 311,94).<\/span><\/strong><\/p>\n

Studium<\/strong><\/span><\/p>\n

Tato studie v re\u00e1ln\u00e9m sv\u011bt\u011b srovn\u00e1v\u00e1 \u00famrtnost na myokarditidu u osob o\u010dkovan\u00fdch proti SARS-CoV-2 s b\u011b\u017enou populac\u00ed v Japonsku.\u00a0Studie je zalo\u017eena na materi\u00e1lech a z\u00e1sadn\u00edch statistik\u00e1ch poskytnut\u00fdch japonskou vl\u00e1dou.<\/span><\/p>\n

Tato japonsk\u00e1 studie je st\u00e1le v p\u0159edti\u0161t\u011bn\u00e9 verzi a zahrnuje 99 834 543 lid\u00ed ve v\u011bku 12 a v\u00edce let, kte\u0159\u00ed byli do \u00fanora 2022 jednou nebo dvakr\u00e1t o\u010dkov\u00e1ni proti COVID-19.\u00a0Auto\u0159i jako referen\u010dn\u00ed populaci pou\u017e\u00edvaj\u00ed ty lidi, kte\u0159\u00ed byli v letech 2017 a\u017e 2019 star\u0161\u00ed 10 let.<\/span><\/p>\n

V\u00fdsledek<\/strong><\/span><\/p>\n

Auto\u0159i uv\u00e1d\u011bj\u00ed v medXriv, \u017ee po\u010det \u00famrt\u00ed na myokarditidu, kter\u00e1 splnila krit\u00e9ria pro za\u0159azen\u00ed, byl 38 p\u0159\u00edpad\u016f.\u00a0MMRR (95% 16 interval spolehlivosti) byl 4,03 (0,77 a\u017e 13,60) ve v\u011bkov\u00e9 skupin\u011b 20 let, 6,69 (2,24 a\u017e 16,71) ve v\u011bkov\u00e9 skupin\u011b 30 let a 3,89 (1,48 a\u017e 8,64) 17 let ve v\u011bku 40-17 let. – star\u0161\u00ed v\u011bkov\u00e1 skupina.\u00a0SMR pro myokarditidu byla 2,01 (1,44 a\u017e 2,80) pro b\u011b\u017enou o\u010dkovanou populaci a 1,65 (1,07 a\u017e 2,55) pro osoby ve v\u011bku 60 let a star\u0161\u00ed.\u00a0Odhadovan\u00e9 hodnoty adMMRR a adSMR byly p\u0159ibli\u017en\u011b \u010dty\u0159ikr\u00e1t vy\u0161\u0161\u00ed ne\u017e hodnoty MMRR a SMR.\u00a0Souhrnn\u00fd MOR pro myokarditidu byl 205,60 (133,52 a\u017e 311,94).<\/span><\/p>\n

Diskuse<\/strong><\/span><\/p>\n

V\u00fdsledky t\u00e9to studie maj\u00ed p\u0159evratn\u00e9 d\u016fsledky.\u00a0O\u010dkov\u00e1n\u00ed proti SARS-CoV-2 bylo spojeno s vy\u0161\u0161\u00edm rizikem \u00famrt\u00ed na myokarditidu, a to nejen u mlad\u00fdch dosp\u011bl\u00fdch, ale ve v\u0161ech v\u011bkov\u00fdch skupin\u00e1ch v\u010detn\u011b senior\u016f.\u00a0Vzhledem k \u00fa\u010dinku o\u010dkov\u00e1n\u00ed na zdrav\u00e9 jedince auto\u0159i nazna\u010duj\u00ed, \u017ee riziko tohoto z\u00e1va\u017en\u00e9ho vedlej\u0161\u00edho \u00fa\u010dinku by mohlo b\u00fdt \u010dty\u0159ikr\u00e1t nebo vy\u0161\u0161\u00ed ne\u017e zjevn\u00e9 riziko \u00famrt\u00ed na myokarditidu.\u00a0Zd\u016fraz\u0148uj\u00ed, \u017ee je t\u0159eba vz\u00edt v \u00favahu i mo\u017en\u00e9 podkryt\u00ed.\u00a0Na z\u00e1klad\u011b t\u00e9to studie by riziko myokarditidy po o\u010dkov\u00e1n\u00ed proti SARS-CoV-2-24 mohlo b\u00fdt vy\u0161\u0161\u00ed, ne\u017e bylo d\u0159\u00edve hl\u00e1\u0161eno.\u00a0Tato studie je v souladu s dal\u0161\u00edmi d\u016fkazy, \u017ee bezpe\u010dnost vakc\u00edny je t\u0159eba p\u0159ehodnotit.<\/span><\/p>\n

Omezen\u00ed<\/strong><\/span><\/p>\n

Tato studie m\u00e1 \u0159adu omezen\u00ed.\u00a0P\u0159edtisk si m\u016f\u017eete p\u0159e\u010d\u00edst zde.\u00a0TrialSite poznamen\u00e1v\u00e1, \u017ee tato japonsk\u00e1 organizace je zn\u00e1m\u00e1 svou d\u016fkladnou prac\u00ed.<\/span><\/p>\n

Vedouc\u00ed v\u00fdzkumu\/investor<\/strong><\/span><\/p>\n

\n
\"\"<\/figure>\n<\/div>\n

Sintaroo Watanabe, MD, PhD, Japan Marine United Corporation, Kure Shipyard, Kure, Japonsko<\/span><\/p>\n

Rokuro Hama, MD, Neziskov\u00e1 organizace Japonsk\u00fd institut farmakovigilance (Med Check), Osaka, Japonsko, odpov\u00eddaj\u00edc\u00ed autor)<\/span><\/p>\n

V\u00fdzva k akci: Jak\u00fd je dopad t\u00e9to studie?\u00a0M\u011blo by b\u00fdt p\u0159ezkoum\u00e1no, ale vzhledem k rizik\u016fm je t\u0159eba podniknout dal\u0161\u00ed nal\u00e9hav\u00e1 opat\u0159en\u00ed?<\/span><\/p>\n

Studie na\u00a0<\/span>medRvix<\/span><\/a><\/p>\n

 <\/p>\n<\/div>\n<\/div>\n

\n
\n

ZDROJ<\/a><\/span><\/h3>\n

 <\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Extr\u00e9mn\u011b vysok\u00e1 pravd\u011bpodobnost \u00famrt\u00ed na myokarditidu Dal\u0161\u00ed studie, tentokr\u00e1t z Japonska, vyvol\u00e1v\u00e1 obavy ohledn\u011b bezpe\u010dnostn\u00edch…<\/p>\n","protected":false},"author":2,"featured_media":17219,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[105,2340,839,651],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/17218"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=17218"}],"version-history":[{"count":1,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/17218\/revisions"}],"predecessor-version":[{"id":17220,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/17218\/revisions\/17220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/17219"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=17218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=17218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=17218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}